IUPAC: 5-(aminomethyl)-1,2-oxazol-3(2H)-one · 5-(aminomethyl)isoxazol-3-ol · C₄H₆N₂O₂ · MW 114.10 g/mol · CAS 2763-96-4 · ChEMBL CHEMBL273481
Muscimol (agarin, pantherine). The psychoactive isoxazole of Amanita muscaria (fly agaric) and A. pantherina (panther cap) — a conformationally locked structural analog of GABA and a potent DIRECT orthosteric agonist of the GABAA receptor. Unlike benzodiazepines, which are allosteric modulators that merely amplify GABA, muscimol binds the GABA orthosteric site itself and gates the channel — it is a switch, not a gain knob. Non-serotonergic: nothing to do with psilocybin. Sedative · dissociative · oneiric · deliriant at dose.
Muscimol is the pharmacological opposite of a benzodiazepine. Where diazepam is a positive allosteric modulator that binds the α+/γ2− "benzodiazepine site" and does nothing without ambient GABA, muscimol binds the orthosteric GABA site itself — the two β+/α− interfaces of the pentamer — and activates the channel directly. It is a conformationally restricted bioisostere of GABA: the 3-isoxazolol ring is an anionic carboxylate surrogate and the aminomethyl group supplies the cationic amine, reproducing the zwitterionic pharmacophore of γ-aminobutyric acid but rigidly pre-organized. That rigidity is why muscimol binds GABAA with higher affinity than GABA itself (Ki in the low-nanomolar range) and behaves as a full — sometimes super-maximal — agonist at the synaptic receptor.
Muscimol occupies the β+/α− orthosteric pocket where GABA normally binds — the aromatic box of β-Tyr/Phe residues and the arginine that anchors the carboxylate surrogate. This is the agonist site, not the allosteric BZD site diazepam and the "z-drugs" exploit.
Occupancy triggers loop-C closure and the ECD→TMD conformational wave that opens the Cl⁻/HCO₃⁻ pore. Muscimol opens the channel on its own; it does not require endogenous GABA to be present. That is the core mechanistic contrast with every benzodiazepine.
Because the isoxazole locks the bioactive conformation, muscimol pays little conformational-entropy penalty on binding — displacing [³H]GABA and [³H]muscimol at Ki ≈ 4–11 nM, tighter than GABA's own affinity. It is the canonical radioligand ([³H]muscimol) for mapping GABAA density.
Muscimol is broadly active across αβγ synaptic subtypes (functional EC₅₀ ≈ 50–410 nM at α5/α3/α2 β2γ2) and at extrasynaptic δ-containing receptors that mediate tonic inhibition — the substrate of its heavy, "leaden" sedation. It is essentially non-selective across the GABAA family.
At the homopentameric ρ (rho) subtype — historically "GABAC" — muscimol is a weaker partial agonist (EC₅₀ ≈ 0.7–1.4 µM). The 3D structure on the right (PDB 9G5Q) is exactly this ρ1 receptor caught with muscimol in the orthosteric pocket.
Muscimol has no meaningful action at 5-HT2A or the serotonin system. This is the fault line with psilocybin/psilocin: Amanita intoxication is GABAergic sedation-dissociation, not a classic serotonergic psychedelic. Different receptor, different experience, different risks.
The behavioural signature follows from the pharmacology: broad, direct GABAA activation drives sedation, ataxia, myoclonic twitching, dysmetropsia (the "Alice-in-Wonderland" macropsia/micropsia), dreamlike (oneiric) and dissociative states, and anterograde amnesia. It is a depressant that reads as dissociative because the inhibition is deep and globally distributed rather than circuit-selective.
The pharmacology of a fly-agaric dose is really the pharmacology of two molecules. Fresh Amanita muscaria contains mostly ibotenic acid — a conformationally restricted glutamate analog that is an agonist at NMDA and other glutamate receptors, excitotoxic, and the chief source of the nausea, vomiting and delirium of raw-mushroom poisoning. Ibotenic acid is muscimol's prodrug: it undergoes decarboxylation (loss of CO₂) to muscimol on drying, aging, heating, or in the acidic stomach. Traditional preparation — drying the caps, gentle heating, or simmering — deliberately shifts the ibotenic-acid → muscimol ratio toward the sedative, less-toxic agonist. Raw or under-processed material is more emetic, more excitotoxic, and less predictable.
Conversion & clearance cascade: decarboxylation occurs largely before and during absorption; a substantial fraction of absorbed muscimol is then excreted intact in urine within hours.
Renal excretion of intact muscimol is the pharmacological basis of the well-documented Siberian folklore in which the urine of an intoxicated person (or reindeer) was consumed to recycle the active drug: muscimol survives first-pass and is passed largely unmetabolized, so the urine carries a cleaner, less-toxic dose than the raw mushroom (which is loaded with ibotenic acid). Not a recommendation — a mechanistic footnote that happens to be true.
Because dosing is governed by fungal chemistry, not a pill, exposure is inherently uncontrolled: muscimol and ibotenic-acid content vary several-fold between caps, populations, seasons, and drying methods. There is no reliable "standard dose" of a wild mushroom, and A. pantherina typically carries higher toxin loads than A. muscaria.
The subjective state produced by Amanita is categorically different from that of a serotonergic psychedelic. There is little of the visual geometry, ego dissolution, or emotional openness characteristic of psilocybin. Instead the profile is depressant and dissociative: waves of heavy sedation alternating with agitation, dreamlike lucid/semi-conscious episodes, distortions of size and distance, muscle twitching, and frequently amnesia for the peak. The mechanism is not mystery — it is deep, non-selective GABAA activation with an excitotoxic overlay from residual ibotenic acid.
Direct orthosteric agonism across synaptic (αβγ) and extrasynaptic (δ) GABAA receptors produces widespread cortical and subcortical inhibition — sedation, ataxia, hypnosis, anticonvulsant tone, and the dreamlike/oneiric quality. Tonic inhibition via δ-containing extrasynaptic receptors underwrites the "leaden," dissociative depth that distinguishes it from ordinary sedation.
The un-decarboxylated fraction acts as an NMDA/glutamate-receptor agonist: nausea and vomiting, agitation, fasciculations and myoclonus, and — at high load — a hyperexcitable delirium and seizure risk. The clinical picture of raw-mushroom poisoning is this GABAergic-sedative / glutamatergic-excitatory tug-of-war, which is why presentations swing between somnolence and agitation.
Macropsia/micropsia and altered time and body perception (the literary "Alice-in-Wonderland" effects long linked to fly agaric), vivid dream-logic imagery, and lucid-dream-like intervals. This is perceptual distortion born of disrupted cortical gain control under heavy inhibition — not the structured serotonergic hallucinosis of a 5-HT2A agonist.
No relevant 5-HT2A engagement, no serotonin-syndrome axis, no cross-tolerance with psilocybin/LSD. Categorizing Amanita with "magic mushrooms" is a pharmacological error with real consequences: the risk profile (sedation, delirium, respiratory-depressant synergy) is that of a GABAergic depressant, not a classic psychedelic. As a research tool, focal muscimol injection is used to reversibly silence a brain region — a chemical "off switch," the antithesis of a psychedelic.
Net: muscimol is best understood as a naturally occurring, orally active GABAA full agonist with a deliriant edge, delivered inside a mushroom that also contains an excitotoxic glutamate agonist. The experience is a sedative-dissociative-oneiric state whose character and hazards are set by GABAergic and glutamatergic pharmacology — and by how thoroughly the mushroom was dried and cooked.
Evidence-based, non-judgmental. Amanita is not "just a mushroom high," and it is not a psilocybin mushroom. Its risks are dominated by ibotenic-acid toxicity, wildly variable potency, misidentification, and depressant synergy. Fatalities from muscimol/ibotenic alone are rare, but serious poisonings and dangerous combinations are not.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
GABAA (rat)
[³H]GABA displacement · brain
|
Ki = 4 nM
JMC 1980
|
Agonist | |
|
GABAA (human)
[³H]GABA displ. · cerebellum
|
Ki = 11 nM
JMC 1980
|
Agonist | |
|
GABAA
[³H]muscimol self-displ.
|
Ki = 6–7 nM
JMC 2013 / EJMC 2014
|
Agonist | |
|
α5β2γ2
GABAA · functional (FLIPR)
|
EC₅₀ = 54 nM
JMC 2013
|
Full agonist | |
|
α3β2γ2
GABAA · functional (FLIPR)
|
EC₅₀ = 210 nM
JMC 2013
|
Full agonist | |
|
GABAA-ρ1
homopentamer (PDB 9G5Q subtype)
|
EC₅₀ = 0.7–1.4 µM
JMC 2008/2013
|
Partial agonist |